A Conversation with AAX Biotech’s CEO, Maria Lisa Knudsen
November 3, 2025
At this year’s Nordic Life Science Days, we sat down with Maria Lisa Knudsen, PhD, CEO of AAX Biotech AB, a rising Swedish biotech transforming how antibody drugs are designed. With its patented antibody–antigen crosslinking platform, AAX Biotech is pushing the boundaries of antibody engineering, creating therapies that are more stable, more effective, and longer lasting, addressing critical gaps in today’s treatment landscape.
In our conversation, Maria Lisa shares what drives AAX Biotech’s innovation, the unmet medical need they aim to solve, and how they manage to stand out in a crowded biotech space through unique science and strong partnerships. She also reveals how the team keeps momentum in a fast-moving industry and gives a glimpse into what’s next for the company following their appearance in the NLSDays pitch competition.
Watch the full interview to discover how AAX Biotech is redefining the future of antibody-based therapies.
Video edited by Olesia Karvetskaia